BridgeBio Pharma, Inc.
$68.37+3.59%(+$2.37)
TickerSpark Score
54/100
33
Valuation
60
Profitability
55
Growth
60
Health
60
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BBIO research report →
52-Week Range69% of range
Low $31.77
Current $68.37
High $84.94
Companywww.bridgebio.com
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development.
- CEO
- Neil Kumar
- IPO
- 2019
- Employees
- 725
- HQ
- Palo Alto, CA, US
Price Chart
+103.65% · this period
Valuation
- Market Cap
- $13.39B
- P/E
- -18.35
- P/S
- 23.09
- P/B
- -5.87
- EV/EBITDA
- -26.45
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 93.78%
- Op Margin
- -98.40%
- Net Margin
- -125.17%
- ROE
- 36.00%
- ROIC
- -57.94%
Growth & Income
- Revenue
- $502.08M · 126.26%
- Net Income
- $-729,306,000 · -36.12%
- EPS
- $-3.79 · -31.60%
- Op Income
- $-569,087,000
- FCF YoY
- 14.31%
Performance & Tape
- 52W High
- $84.94
- 52W Low
- $31.77
- 50D MA
- $71.35
- 200D MA
- $65.65
- Beta
- 1.02
- Avg Volume
- 2.48M
Get TickerSpark's AI analysis on BBIO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 16, 26 | Trimarchi Thomas | other | 22,781 |
| May 18, 26 | Trimarchi Thomas | sell | 10,456 |
| May 18, 26 | Trimarchi Thomas | sell | 3,195 |
| May 16, 26 | Kumar Neil | other | 6,519 |
| May 16, 26 | Kumar Neil | other | 11,553 |
| May 16, 26 | Kumar Neil | other | 19,599 |
| May 16, 26 | Kumar Neil | other | 36,236 |
| May 16, 26 | Kumar Neil | other | 33,544 |
| May 16, 26 | Kumar Neil | other | 19,599 |
| May 16, 26 | Kumar Neil | other | 11,553 |
Our BBIO Coverage
We haven't published any research on BBIO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BBIO Report →Similar Companies
RVMD+2.45%
Revolution Medicines, Inc.
$150.91
IONS+1.44%
Ionis Pharmaceuticals, Inc.
$74.90
ASND+1.00%
Ascendis Pharma A/S
$240.35
SMMT+9.62%
Summit Therapeutics Inc.
$17.37
ROIV+13.63%
Roivant Sciences Ltd.
$32.05
MRNA+5.82%
Moderna, Inc.
$48.38
BMRN+0.12%
BioMarin Pharmaceutical Inc.
$49.87
EXEL+2.57%
Exelixis, Inc.
$49.92